Lead Product(s): Brazikumab
Therapeutic Area: Gastroenterology
Highest Development Status: Phase II/ Phase III Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Divestment January 27, 2020
AstraZeneca will acquire brazikumab, in Phase 2b/3 development for Crohn's Disease and in Phase 2 development for ulcerative colitis, including global development and commercial rights.